Kaposi Sarcoma in people living with HIV: is it water under the bridge?

Main Article Content

chiara papalini
Lucia Brescini
Laura Curci
Sabrina Bastianelli
Francesco Barchiesi
Andrea Giacometti
Daniela Francisci


Kaposi Sarcoma, HIV, AIDS, mortality, antiretroviral therapy


Kaposi Sarcoma (KS) is still common among people living with HIV (PLWH). A lot of literature illustrated risk factors associated with KS occurrence, while the aim of our study is to investigate possible factors influencing 5-year survival.



Download data is not yet available.

Abstract 384
PDF Downloads 505
HTML Downloads 196


[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
[2] Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual Transmission and the Natural History of Human Herpesvirus 8 Infection. N Engl J Med. 1998;338:948-54.
[3] Poizot-Martin I, Obry-Roguet V, Duvivier C, Lions C, Huleux T, Jacomet C, Ferry T, Cheret A, Allavena C, Bani-Sadr F, Palich R, Cabié A, Fresard A, Pugliese P, Delobel P, Lamaury I, Hustache-Mathieu L, Brégigeon S, Makinson A, Rey D; Dat'AIDS study group. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015. J Eur Acad Dermatol Venereol. 2020;34(5):1065-73.
[4] Liu Z, Fang Q, Zuo J, Minhas V, Wood C, Zhang T. The world-wide incidence of Kaposi's sarcoma in the HIV/AIDS era. HIV Med. 2018;19(5):355-364. Epub 2018 Jan 25
[5] Grabar S, Costagliola D. Epidemiology of Kaposi's Sarcoma. Cancers (Basel). 2021;13(22):5692
[6] Ibrahim Khalil A, Franceschi S, de Martel C, Bray F, Clifford GM. Burden of Kaposi sarcoma according to HIV status: A systematic review and global analysis. Int J Cancer. 2022;150(12):1948-57.
[7] AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord. Comparison of Kaposi sarcoma risk in human immunodeficiency virus-positive adults across 5 continents: a multiregional multicohort study. Clin Infect Dis. 2017;65:1316-26.
[8] Papalini C, Paciosi F, Schiaroli E, Pierucci S, Busti C, Bozza S, Mencacci A, Francisci D. Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV. Mediterr J Hematol Infect Dis. 2020;12(1):e2020080.
[9] Schiaroli E, De Socio GV, Gabrielli C, Papalini C, Nofri M, Baldelli F, Francisci D. Partial Achievement of the 90-90-90 UNAIDS Target in a Cohort of HIV Infected Patients from Central Italy. Mediterr J Hematol Infect Dis. 2020;12(1):e2020017.
[10] Papalini C, Lagi F, Schiaroli E, Sterrantino G, Francisci D. Transgender people living with HIV: characteristics and comparison to homosexual and heterosexual cisgender patients in two Italian teaching hospitals. Int J STD AIDS. 2021;32(2):194-198. Epub 2020 Dec 16
[11] Stolka K, Ndom P, Hemingway-Foday J, Iriondo-Perez J, Miley W, Labo N, Stella J, Abassora M, Woelk G, Ryder R, Whitby D, Smith JS. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. Cancer Epidemiol. 2014;38(2):137-43. Epub 2014 Mar 13
[12] Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, De Castro N, Berger J-L, Dupont C, Lavolé A, Pradier C, Salmon D, Simon A, Martinez V, Costagliola D, Grabar S; French Hospital Database on HIV–ANRS CO4 Cohort. Risk of AIDS-Defining Cancers Among HIV-1–Infected Patients in France Between 1992 and 2009: Results From the FHDH-ANRS CO4 Cohort. Clin Infect Dis. 2013;57:1638-47.
[13] Caby, F.; Guiguet, M.; Weiss, L.; Winston, A.; Miro, J.M.; Konopnicki, D.; Le Moing, V.; Bonnet, F.; Reiss, P.; Mussini, C, Poizot-Martin I, Taylor N, Skoutelis A, Meyer L, Goujard C, Bartmeyer B, Boesecke C, Antinori A, Quiros-Roldan E, Wittkop L, Frederiksen C, Castagna A, Thurnheer MC, Svedhem V, Jose S, Costagliola D, Mary-Krause M, Grabar S; (CD4/CD8 ratio and cancer risk) project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clin Infect Dis. 2020;73:50-59.
[14] Regine V, Pugliese L, Boros S, Santaquilani M, Ferri M, Suligoi B. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2021. Notiziario. 2022;35(11)
[15] Rohrmus B, Thoma-Greber EM, Rocken M, Bogner JR. Outlook in oral and cutaneous Kaposi’s sarcoma. Lancet. 2000;356:2160.
[16] Kowalkowski MA, Kramer JR, Richardson PR, Suteria I, Chiao EY. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection. Clin Infect Dis. 2015;60(9):1405-14.
[17] Gantt S, Cattamanchi A, Krantz E, Magaret A, Selke S, Kuntz SR, Huang ML, Corey L, Wald A, Casper C. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol. 2014;60(2):127-32
[18] Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. The HIV protease inhibitor nelfinavir inhibits Kaposi’s sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55(6):2696-703
[19] Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol. 2003;4(9):537-47
[20] Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi’s sarcoma patients treated with chemotherapy. HIV Clin Trials. 2003;4:107-14
[21] Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS. 1999;13:2105-11
[22] Mocroft A, Kirk O, Clumeck, N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Phillips AN, Lundgren J. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003. Cancer. 2004;100:2644-54.
[23] Cancer ProjectWorking Group for the Collaboration of Observational HIV Epidemiological Research Europe Study in EuroCoord. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clin. Infect. Dis. 2016, 63, 1373-79.
[24] Lacombe JM, Boue F, Grabar S, Viget N, Gazaignes S, Lascaux-Cametz AS, Pacanowski J, Partisani M, Launay O, Matheron S, Rosenthal E, Rouveix E, Tattevin P, de Truchis P, Costagliola D, Goedert JJ. Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. AIDS. 2013;27:635-43.
[25] Lodi S, Guiguet M, Costagliola, D, Fisher M, De Luca A, Porter K. The CASCADE Collaboration Kaposi Sarcoma Incidence and Survival Among HIV-Infected HomosexualMen After HIV Seroconversion. J. Natl. Cancer Inst. 2010;102:784-92.
[26] Group I.S.S. Lundgren, JD, Babiker AG, Gordin, F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795–807.